Tonix Pharmaceuticals Holding Corp. (TNXP)
TNXP Stock Price Chart
Explore Tonix Pharmaceuticals Holding Corp. interactive price chart. Choose custom timeframes to analyze TNXP price movements and trends.
TNXP Company Profile
Discover essential business fundamentals and corporate details for Tonix Pharmaceuticals Holding Corp. (TNXP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 May 2012
Employees
81.00
Website
https://www.tonixpharma.comCEO
Seth Lederman
Description
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
TNXP Financial Timeline
Browse a chronological timeline of Tonix Pharmaceuticals Holding Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$2.64, while revenue estimate is $7.72m.
Earnings released on 11 May 2026
EPS came in at -$2.93 falling short of the estimated -$2.54 by -15.35%, while revenue for the quarter reached $6.88m , beating expectations by +12.29%.
Earnings released on 12 Mar 2026
EPS came in at -$3.98 falling short of the estimated -$3.16 by -25.95%, while revenue for the quarter reached $5.39m , beating expectations by +81.69%.
Earnings released on 10 Nov 2025
EPS came in at -$3.59 matching the estimated -$3.59, while revenue for the quarter reached $3.29m , beating expectations by +10.90%.
Earnings released on 11 Aug 2025
EPS came in at -$3.86 falling short of the estimated -$3.10 by -24.52%, while revenue for the quarter reached $2.00m , missing expectations by -17.89%.
Earnings released on 12 May 2025
EPS came in at -$2.84 surpassing the estimated -$3.23 by +12.07%, while revenue for the quarter reached $2.43m , missing expectations by -8.34%.
Earnings released on 18 Mar 2025
EPS came in at -$9.77 falling short of the estimated -$6.23 by -56.82%, while revenue for the quarter reached $2.58m , missing expectations by -19.31%.
Stock split effective on 5 Feb 2025
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2024
EPS came in at -$23.00 surpassing the estimated -$203.00 by +88.67%, while revenue for the quarter reached $2.82m , missing expectations by -17.00%.
Earnings released on 16 Aug 2024
EPS came in at -$1.93k falling short of the estimated -$991.00 by -94.55%, while revenue for the quarter reached $2.21m , missing expectations by -38.32%.
Stock split effective on 10 Jun 2024
Shares were split 1 : 32 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 Apr 2024
EPS came in at -$2.75k surpassing the estimated -$4.98k by +44.87%, while revenue for the quarter reached $2.48m , missing expectations by -34.68%.
Earnings released on 25 Mar 2024
EPS came in at -$0.86 surpassing the estimated -$1.64 by +47.56%, while revenue for the quarter reached $3.78m , missing expectations by -1.33%.
Earnings released on 9 Nov 2023
EPS came in at -$5.85k falling short of the estimated -$4.76k by -22.82%, while revenue for the quarter reached $3.99m , missing expectations by -22.24%.
Earnings released on 10 Aug 2023
EPS came in at -$8.56k surpassing the estimated -$8.88k by +3.60%.
Stock split effective on 10 May 2023
Shares were split 4 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2023
EPS came in at -$10.38k falling short of the estimated -$7.99k by -30.00%, while revenue for the quarter reached $33.90m .
Earnings released on 13 Mar 2023
EPS came in at -$11.18k surpassing the estimated -$12.58k by +11.11%.
Earnings released on 7 Nov 2022
EPS came in at -$13.78k surpassing the estimated -$14.38k by +4.17%.
Earnings released on 8 Aug 2022
EPS came in at -$24.36k surpassing the estimated -$29.15k by +16.44%, while revenue for the quarter reached $9.03m .
Stock split effective on 17 May 2022
Shares were split 1 : 32 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2022
EPS came in at -$31.90k matching the estimated -$31.90k.
Earnings released on 14 Mar 2022
EPS came in at -$44.66k matching the estimated -$44.66k.
Earnings released on 8 Nov 2021
EPS came in at -$31.90k surpassing the estimated -$44.66k by +28.57%.
Earnings released on 9 Aug 2021
EPS came in at -$44.66k matching the estimated -$44.66k.
TNXP Stock Performance
Access detailed TNXP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
